Kelso Pharma appoints life sciences chief as chairman

Kelso Pharma, the rising speciality pharma enterprise, has appointed senior Life Sciences govt, Gordon Cameron OBE, as its Non-Government Chairman.

A senior govt with 25 years’ Board-level expertise in non-public fairness and plc listed companies, Gordon has labored within the UK and US, primarily in biotech and pharmaceutical companies together with each contract analysis organisations (CRO) and contract improvement and manufacturing organisations (CDMO). Initially with Ernst & Younger, Gordon had a number of years in funding banking with Rothschild earlier than turning into CFO after which CEO of FTSE-250 worldwide vaccines firm, Acambis plc.  Gordon has spent the final 15 years as CFO with Quotient Sciences, a private-equity backed worldwide CDMO and CRO. Throughout his time there, revenues grew 15-fold.

Kelso Pharma, primarily based within the Scottish Borders city of the identical identify, goals to convey modern, value-added, specialty medicines to the European healthcare markets, offering medicines that enhance the lives of sufferers in a cheap and moral method. Kelso Pharma is rising by way of a mix of firm & product acquisitions, partnerships and natural development, each within the UK and in Europe.

Commenting on the appointment, Kelso Pharma CEO, Dr. Tom Stratford, stated: “We’re thrilled to welcome Gordon to the Kelso Pharma workforce as our Non-Government Chairman. He brings intensive business expertise, in addition to a deep understanding of rising companies beneath non-public fairness possession.

“Gordon’s expertise, skillset and information reveal the calibre of individuals we’re trying to work with at Kelso Pharma. We intention to supply medicines that enhance the lives of sufferers each day and we sit up for working with Gordon as we proceed to develop the enterprise.”

See also  PREVIEW – Will Mars – My Life in One-Liners

Gordon Cameron added: “I’m very excited to be becoming a member of Kelso Pharma at a busy and pivotal time for the enterprise as they give the impression of being to develop, each organically and by acquisition.

“With the intention of offering value-added medicines to the market in an moral method with individuals on the coronary heart of determination making aligns with my very own values and I’m wanting ahead to taking part in an element in driving Kelso Pharma’s development.”